Fronto-striato-thalamic perfusion and clozapine response in treatment- refractory schizophrenic patients. A 99mTc-HMPAO study

Psychiatry Research - Neuroimaging

Volumn 76, Issue 1, 1997, Pages 51-61

  Rodríguez, Vicente Molina ^a,e   Andrée, Richard Montz ^b   Pérez Castejón, M Jesús ^b   Luisa Catalina Zamora, M ^c   Alvaro, Pedro Cuesta ^d   Luis Carreras Delgado, J ^b   Jose Rubia Vila F ^d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

^c Hospital Psiquiatrico San Juan de Dios   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e INSTITUTO PLURIDISCIPLINAR   (Spain)

Author keywords

Clozapine; Non responders; Perfusion differences; Responders; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; THIORIDAZINE; TRIFLUOPERAZINE;

ADULT; ARTICLE; BASAL GANGLION; BRAIN PERFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS;

EID: 0344157425     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4927(97)00057-7     Document Type: Article

References (59)

1. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. APA, Washington, DC.
2. Andreasen, N.C., Arndt, S., Swayze, V., Cizadlo, T., Flaum, M., O'Leary, D., Ehrhard, J.C., Yuh, W.T.C., 1994. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 266, 294-298.
3. 2A receptor gene. Lancet 346, 281-282.
4. Ashby, C.R., Jr., Jiang, L.H., Kassr, R.J., Wang, R.Y., 1990. Electrophysiological characterization of 5-hydroxytryptamine 2 receptors in the rat medial prefrontal cortex. Journal of Pharmacology and Experimental Therapeutics 252, 171-178.
5. Bartlett, E.J., Wolkin, A., Brodie, J.D., 1991. Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia. Psychiatry Research 40, 115-124.
6. 1 dopamine receptors. Neuroscience 67, 34-38.
7. Buchsbaum, M.S., Someya, T., Teng, C.Y., Abel, L., Chin, S., Najafi, A., Haier, R.J., Wu, J., Bunney, W.E., 1996. PET and MRI of the thalamus in never-medicated patients with schizophrenia. American Journal of Psychiatry 153, 191-199.
8. Buchsbaum, M.S., Potkin, S.G., Marshall, J.F., Lottenberg, S., Teng, C., Heh, C.W., Tafalla, R., Reynolds, C., Abel, L., Plon, L., Bunney, W.E., Jr. 1992. Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. Neuropsychopharmacology 6, 155-163.
9. Buchsbaum, M.S., Wu, J.C., DeLisi, L.E., Holcomb, H.H., Hazlett, E., Cooper-Langston, K., Kessler, R., 1987. Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: differences between normal controls and schizophrenic patients. Biological Psychiatry 22, 479-494.
10. Carlsson, M., Carlsson, A., 1990. Interactions between glutamatergic and monoaminergic systems within the basal ganglia. Implications for schizophrenia and Parkinson's disease. Trends in Neuroscience 13, 172-276.
11. Chakos, M.H., Lieberman, J.A., Alvir, J., Bilder, R., Ashtari, M., 1995. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 345, 456-457.
12. Cohen, B.M., Wan, W., 1996. The thalamus as a site of action of antipsychotic drugs. American Journal of Psychiatry 153, 104-106.
13. 2 receptors in schizophrenia studied in vivo. Lancet 1, 224.
14. Dewey, S.L., Smith, G.S., Logan, J., Brodie, J.D., 1993. Modulation of central cholinergic activity by GABA and serotonin: PET studies with HC-benztropine in primates. Neu-ropsychopharmacology, 8, 371-376.
15. Dragunow, M., Faull, R., 1989. The use of c-fos as a metabolic marker in neuronal pathway tracing. Journal of Neuroscience Methods 29, 261-265.
16. Ebmeier, K.P., Lawrie, S.M., Blackwood, D.H.R., et al., 1995. Hypofrontality revisited: a high resolution single photon emission computed tomography in schizophrenia. Journal of Neurology, Neurosurgery and Psychiatry 58, 452-456.
17. 11C-raclopride. Archives of General Psychiatry 47, 213-219.
18. 2 receptor occupancy in patients treated with classical neuroleptics and clozapine. Archives of General Psychiatry 49, 538-544.
19. Friedman, L., Knutson, L., Shurell, M., Meltzer, H.Y., 1991. Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biological Psychiatry 29, 865-877.
20. Gemmell, H.G., Evans, N.S.T., Besson, J.A.O., 1990. Regional cerebral blood flow imaging: a quantitative comparison of technetium-99-m-HMPAO SPECT with C11-O2 PET. Journal of Nuclear Medicine 31, 1595-1600.
21. Graybiel, A.M., 1990. Neurotransmitters and neuromodulators in the basal ganglia. Trends in Neuroscience 13, 244-254.
22. 2 receptor density in neuroleptic-naive schizophrenics studied with positron emission tomography. In: Racagni, G., Brunello, N., Fukuda, T. (Eds.), Biological Psychiatry, vol. 2. Excerpta Medica, Amsterdam, pp. 386-387.
23. Holcomb, H.H., Cascella, N.G., Thaker, G.K., Medoff, D.R., Dannals, R.F., Tamminga, C.A.T., 1996. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. American Journal of Psychiatry 153, 41-49.
24. Holman, B.L., Mendelson, J., Garada, B., Teoh, S.K., Allgring, E., Johnson, K.A., Mello, N.K., 1993. Regional cerebral blood flow improves with treatment in chronic cocaine polydrug users. Journal of Nuclear Medicine 34, 723-727.
25. Honingfeld, G., Patin, J., 1989. Predictors of response to clozapine therapy. Psychopharmacology 99, S64-S67.
26. Clozaril Collaborative Study Group. Kane, J.M., Honingfeld, G., Singer, J., Meltzer, H.Y., 1988. Clozapine for the treatment-refractory schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789-796.
27. Jin, Y., Potkin, S.G., Sandman, C., 1995. Clozapine increases EEC photic driving in clinical responders. Schizophrenia Bulletin 21, 263-268.
28. Joyce, J.N., Sapp, D.W., Marshall, J.F., 1986. Human striatal dopamine receptors are organized in compartments. Proceedings of the National Academy of Sciences USA 83, 8002-8006.
29. 2 dopamine receptors in 56 patients taking various neuroleptics. American Journal of Psychiatry 153, 183-190.
30. Lieberman, J.A., Safferman, A.Z., Pollack, S., Szymansky, S., Johns, C., Howard, A., Kronig, M.H., Brookstein, P., Kane, J.M., 1994. Clinical effects of clozapine in chronic schizophrenia: treatment response and predictors of outcome. American Journal of Psychiatry 151, 1744-1752.
31. London, E.D., Cascella, N.G., Wong, D.F., Philips, R.L., Dannals, R.F., Links, J.M., Herning, R., Grayson, R., Jaffe, J.H., Wagner, H.N., Jr., 1990. Cocaine-induced reduction of glucose utilization in human brain. A study using positron emission tomography and fluorine-18 fluoro-deoxyglucose. Archives of General Psychiatry 47, 567-574.
32. 2 receptors in human brain. Journal of Neurochemistry 43, 1068-1071.
33. 76br-bromospiperone in untreated schizophrenic patients. American Journal of Psychiatry 147, 44-50.
34. Mega, M.S., Cummings, J.L., 1994. Frontal subcortical circuits and neuropsychiatric disorders. Journal of Neuropsychiatry and Clinical Neuroscience 6, 358-370.
35. Meltzer, H.Y., Bastani, B., Young Kwon, K., Ramirez, L.F., Burnett, S., Sharpe, J., 1989. A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology 99, S68-S72.
36. Minoshima, S., Koeppe, R., Frey, K.A., 1994. Sterotactic PET atlas of the human brain: aid for the visual interpretation of functional brain images. Journal of Nuclear Medicine 35, 949-954.
37. Molina, V., Montz, R., Pérez-Castejón, M.J., et al., 1996. SPECT study of regional cerebral perfusion in neuroleptic-resistant patients who responded or did not respond to clozapine. American Journal of Psychiatry 153, 1343-1346.
38. Nieuwenhuys, R., Voogd, J., Van Huizen, C., 1988. The Human Nervous System: A Synopsis and Atlas, third ed. Springer-Verlag, New York.
39. Niznik, H.B., Van Tol, H.H.M., 1992. Dopamine receptor genes: new tools for molecular psychiatry. Journal of Psychiatry and Neuroscience 17, 158-180.
40. Nordström, A.L., Farde, L., Halldin, C., 1993. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110, 365-367.
41. 11C]-N-methyl-piperone. Psychiatry Research: Neuroimaging 61, 67-83.
42. Pickar, D., Owen, R.R., Liman, R.E., Konicki, P.E., Gutirrez, R., Rapoport, M.H., 1992. Clinical and biological response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Archives of General Psychiatry 49, 345-353.
43. Potkin, S.G., Buchsbaum, M.S., Jin, Y., Tang, Ch., Telfor, J., Friedman, G., Lottenberg, S., Najafi, A., Gulasekaram, B., Costa, J., Richmond, G.H., Bunney, W.E., Jr., 1994. Clozapine effects on glucose metabolic rate in striatum and frontal cortex. Journal of Clinical Psychiatry 55, 63-66.
44. Resnick, S.M., Gur, R., Alavi, A., Gur, R.C., Revich, M., 1988. Positron emission tomography and subcortical glucose metabolism in schizophrenia. Psychiatry Research 24, 1-11.
45. Robertson, G.S., Fibiger, H.C., 1992. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46, 315-328.
46. Robertson, G.S., Fibiger, H.C., 1996. Effects of olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacology 14, 105-110.
47. Rubin, P., Hemmingsen, R., Holm, S., Møller-Madsen, S., Hertel, C., Povlesen, J., Karte, A., 1994. Relationship between brain structure and function in disorders of the schizophrenic spectrum: single photon emission computerized tomography, computerized tomography and psychopathology of first episodes. Acta Psychiatrica Scandinavica 90, 281-289.
48. Schotte, A., Janssen, P.F., Megens, A.A., Leysen, J.E., 1993. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol measured ex vivo by quantitative autoradiography. Brian Research 631, 191-202.
49. Siegel, B.V., Buchsbaum, M.S., Bunney, W.E., Jr., Gottschalk, L.A., Haier, R.J., Lohr, J.B., Lottenberg, S., Najafi, A., Nuechterlein, K.H., Potkin, S.G., Wu, J.C., 1993. Corticalstriatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. American Journal of Psychiatry 150, 1325-1336.
50. Szechtman, H.J., Nahmias, C., Garnett, E.S., Firnan, G., Geisler, S., Pollack, S., Kane, J., 1988. Effects of neuroleptics on altered cerebral glucose metabolism in schizophrenia. Archives of General Psychiatry 45, 523-532.
51. Tamminga, C.A., Thaker, G.K., Buchanan, R., Kirpatrick, B., Alphs, L.D., Chase, T.N., Carpenter, W.T., 1992. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Archives of General Psychiatry 49, 522-530.
52. Turkington, T.G., Jaszack, C.A., Pelizzari, C.A., Harris, C.C., McFall, J.R., Hoffman, J.M., Cohenman, E.R., 1993. Accuracy of registration of PET, SPECT and MR images of a brain phantom. Journal of Nuclear Medicine 34, 1587-1594.
53. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350, 610-614.
54. Vita, A., Bressi, S., Perani, D., Invernizzi, G., Giobbio, G.M., Dieci, M., Garbarini, M., DelSole, A., Fazio, F., 1995. High resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients. American Journal of Psychiatry 152, 8876-8882.
55. Volkow, N.D., Fowler, J.S., Wolf, A.P., Hitzemann, R., Dewey, S., Bendriem, B., Alpert, R., Holf, A., 1991. Changes in brain glucose metabolism in cocaine dependence and withdrawal. American Journal of Psychiatry 148, 621-626.
56. 2 availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14, 169-173.
57. Waldo, M.C., Carey, G., Myles-Worsley, M., 1991. Codistribution of a sensory gating deficit and schizophrenia in multiaffected families. Psychiatry Research 39, 257-268.
58. Wolkin, A., Sanfilipo, M., Duncan, E., Angrist, B., Wolf, A.P., Cooper, T.B., 1996. Blunted change in cerebral glucose utilization after haloperidol treatment of schizophrenic patients with prominent negative symptoms. American Journal of Psychiatry 153, 346-354.
59. 2 receptors in drug-naive schizophrenics. Science 234, 1558-1563.